SEC Company Response from ELITE PHARMACEUTICALS (ELTP) — Dec 4, 2015
ELITE PHARMACEUTICALS INC /NV/ (ELTP) (CIK 0001053369)
Date: Dec. 4, 2015 · CIK: 0001053369 · Accession: 0001144204-15-069399
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-15697
Letter
Securities and Exchange Commission Filed August 10, 2015 Form 10-Q/A for the Quarterly Period Ended September 30, 2015 Filed November 10, 2015 File No. 001-15697
Re: Elite Pharmaceuticals, Inc.
Dear Mr. Rosenberg:
Elite Pharmaceuticals, Inc. hereby acknowledges receipt of the November 20, 2015 SEC Comment Letter regarding the above referenced periodic reports (the “Letter”).
As we have taken significant time reviewing the comments in the Letter and are in the midst of preparing amendments to our Forms 10-Q for the periods ended June 30, 2015 and September 30, 2015 and will need additional time to respond to the comments in the Letter, we hereby request that our time to respond to the Letter be extended to December 21, 2015, 20 business days after the date of the Letter. At this time, we anticipate that we will be able to respond to the Letter on or before the requested extension date.
If you have any questions or comments or are unable to so extend our time to respond, please contact the undersigned at the above address.
Very truly yours,
/s/ Carter Ward
Show Raw Text
CORRESP
1
filename1.htm
December 4, 2015
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attn: Jim B. Rosenberg
Re: Elite Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended
March 31, 2015
Filed June 15, 2015
Form 10-Q for the Quarterly Period
Ended June 30, 2015
Filed August 10, 2015
Form 10-Q/A for the Quarterly Period
Ended September 30, 2015
Filed November 10, 2015
File No. 001-15697
Dear Mr. Rosenberg:
Elite Pharmaceuticals, Inc. hereby acknowledges
receipt of the November 20, 2015 SEC Comment Letter regarding the above referenced periodic reports (the “Letter”).
As we have taken significant time reviewing
the comments in the Letter and are in the midst of preparing amendments to our Forms 10-Q for the periods ended June 30, 2015 and
September 30, 2015 and will need additional time to respond to the comments in the Letter, we hereby request that our time to respond
to the Letter be extended to December 21, 2015, 20 business days after the date of the Letter. At this time, we anticipate that
we will be able to respond to the Letter on or before the requested extension date.
If you have any questions or comments or
are unable to so extend our time to respond, please contact the undersigned at the above address.
Very truly yours,
/s/ Carter Ward
Carter Ward, CFO
165 Ludlow Avenue •
Northvale, NJ 07647 • Ph: (201)750-2646 • Fax: (201)750-2755 www.elitepharma.com